Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab

Volume: 5, Issue: 6, Pages: 951 - 954
Published: Jun 1, 2020
Abstract
C3 glomerulopathy (C3G) is a chronic kidney disease defined by the predominance of C3 deposition in the renal glomeruli.1 C3G is caused by dysregulation of the alternative pathway of complement activation. The majority of C3G is caused by acquired factors—circulating Igs that stabilize the formation of the alternative pathway C3 convertase, C3bBb, which are referred to as C3 nephritic factor (C3NeF).2 In a smaller subset of C3G, autoantibodies...
Paper Details
Title
Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab
Published Date
Jun 1, 2020
Volume
5
Issue
6
Pages
951 - 954
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.